We are live on
!
Find out more
OFM
Omega Fund Management Portfolio holdings
AUM
$163M
1-Year Est. Return
107.06%
This Fund
S&P 500
This Quarter
Est. Return
-17.32%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$163M
AUM Growth
-$123M
(-43%)
Cap. Flow
-$51.4M
Cap. Flow
% of AUM
-31.48%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCAX
Bicara Therapeutics
BCAX
|
+$3.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$36M |
| 2 |
ALMS
Alumis Inc
ALMS
|
+$10.3M |
| 3 |
KMTS
Kestra Medical Technologies
KMTS
|
+$8.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
HCCM
PBO
PCR
BCM
IVGAI
CC
TCGDR
IPWA
Omega Fund Management's Q1 2026 Portfolio in Review
As of Q1 2026, Omega Fund Management held 11 positions worth $163M, down 43% from $287M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Omega Fund Management withdrew a net $51.4M in Q1 2026, closing 1 position and reducing 2 holdings. Its most notable exit was Upstream Bio Inc, an estimated $36M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Omega Fund Management added an estimated $3.23M to Bicara Therapeutics.
- Omega Fund Management added most to Bicara Therapeutics in Q1 2026, an estimated $3.23M increase.
- Omega Fund Management's biggest Q1 2026 reduction was Alumis Inc, cutting an estimated $10.3M.
- Omega Fund Management fully exited Upstream Bio Inc in Q1 2026, selling an estimated $36M.
- Omega Fund Management's ten largest holdings make up 100% of its $163M portfolio in Q1 2026.
- Omega Fund Management opened 0 new positions and closed 1 in Q1 2026.
- Omega Fund Management's portfolio value fell 43% quarter-over-quarter to $163M.
Based on Omega Fund Management's 13F filing for Q1 2026, filed 15 May 2026.